The reckoning begins for biotech-focused Spacs
The clock is ticking for the flood of blank-cheque companies that raised money last year, and competition is only getting hotter.
SITC 2020 – embargo snafu triggers the first movers
The SITC breaks its own embargo, and the ensuing chaos sees Replimune, Iovance and Incyte move.
Seres brings the microbiome back to life
Like many biotechs the group pushed on into phase III after a phase II failure; remarkably, the strategy has worked.
Kevzara's Covid-19 setback shows need for hard evidence
As investors continue to jump on small sparks of hope in the pandemic pipeline Sanofi and Regeneron inject a dose of reality.
